The abstract is read at the publisher; the summary is JClub's.
A cis-genetic proxy for NLRP3 downregulation (19% CRP difference) reproduces ruvonoflast-like biomarker changes but does not reduce ASCVD risk in 575,531 participants.
- Why it matters: NLRP3 inhibition is a promising anti-inflammatory strategy for atherosclerotic cardiovascular disease, but it is unclear whether lowering inflammasome activity translates into cardiovascular benefit.
- What they did: Using 14 NLRP3-locus variants (P<5 x 10^-8; ±100 kb of the NLRP3 transcription start site) from 575,531 participants, Mendelian randomization and colocalization tested effects on immune-cell expression, downstream biomarkers, and outcomes, including 1,387 clinical endpoints.
- The result: Genetically proxied NLRP3 downregulation lowered IL-18 (beta=-0.11) and IL-6 (beta=-0.15) and matched ruvonoflast effects across 8 biomarkers; it reduced recurrent pericarditis (OR 0.68) but slightly increased coronary artery disease (OR 1.06) and peripheral arterial disease (OR 1.10), with no effect on ischaemic stroke (OR 0.98).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.